Mesothelioma Research | Emerging Therapies | Mesothelioma Treatment

Read about relevant up-and-coming therapies for mesothelioma, including those involving pemetrexed (Alimta), anti-mesothelin immunotoxins, antiangiogenic therapies, and gene therapy.

A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses.
Sterman DH, Recio A, Carroll RG, Gillespie CT, Haas A, Vachani A, Kapoor V, Sun J, Hodinka R, Brown JL, Corbley MJ, Parr M, Ho M, Pastan I, Machuzak M, Benedict W, Zhang XQ, Lord EM, Litzky LA, Heitjan DF, June CH, Kaiser LR, Vonderheide RH, Albelda SM, Kanther M. Thoracic Oncology Gene Therapy Program and Abramson Family Cancer Research Institute, University of Pennsylvania Medical Center, Philadelphia, PA 19104-4283, USA. sterman@mail.med.upenn.edu

Cytokine gene therapy for malignant pleural mesothelioma.
Vachani A, Sterman DH, Albelda SM. Thoracic Oncology Research Laboratory, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA. avachani@mail.med.upenn.edu

Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy.
Sterman DH, Recio A, Vachani A, Sun J, Cheung L, DeLong P, Amin KM, Litzky LA, Wilson JM, Kaiser LR, Albelda SM. Thoracic Oncology Research Laboratory, University of Pennsylvania Medical Center, Philadelphia, PA 19104-4283, USA. sterman@mail.med.upenn.edu

Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma.
Sterman DH, Albelda SM. Thoracic Oncology Research Laboratory, Interventional Pulmonology Program, Pulmonary, Allergy and Critical Care Division, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104-4283, USA. sterman@mail.med.upenn.edu

Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
Taylor P, Castagneto B, Dark G, Marangolo M, Scagliotti GV, van Klaveren RJ, Labianca R, Serke M, Schuette W, van Meerbeeck JP, Heigener D, Liu Y, Adachi S, Blatter J, von Pawel J. University Hospital of South Manchester, Manchester, United Kingdom. Paul.Taylor@smuht.nwest.nhs.uk

Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM, Manegold C. Istituto Clinico Humanitas, Rozzano, Italy. armando.santoro@humanitas.it

Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
Jackman DM, Kindler HL, Yeap BY, Fidias P, Salgia R, Lucca J, Morse LK, Ostler PA, Johnson BE, Jänne PA. Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.
Jänne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, Monberg M, Obasaju C, Kindler H. Dana Farber Cancer Institute, Lowe Center for Thoracic Oncology, 44 Binney St, Dana D820A, Boston, MA 02115, USA. pjanne@partners.org

Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.
Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, Pastan I. Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute and Clinical Center, NIH, Bethesda, Maryland 20892-4264, USA. hassanr@mail.nih.gov .

Antiangiogenic therapies for mesothelioma.
Dowell JE, Kindler HL. University of Texas-Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8852, USA. jonathan.dowell@utsouthwestern.edu

Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.
Kindler HL, Herndon JE, Zhang C, Green MR; Cancer and Leukemia Group B. University of Chicago, 5841 S. Maryland Avenue, MC 2115, Chicago, IL 60637, USA. hkindler@medicine.bsd.uchicago.edu

Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
Govindan R, Kratzke RA, Herndon JE 2nd, Niehans GA, Vollmer R, Watson D, Green MR, Kindler HL; Cancer and Leukemia Group B (CALGB 30101). Department of Medicine, Washington University School of Medicine, 4960 Children's Place, Suite 108, St. Louis, MO 63110, USA. rgovinda@im.wustl.edu

Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma.
Kindler HL. Department of Hematology/Oncology, Medical Center, University of Chicago, 5841 South Maryland Avenue, MC 2115, IL 60637-1470, USA. hkindler@medicine.bsd.uchicago.edu

Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.
Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, Chao Q, Jacob S, Turchin H, Gibbs L, Phillips MD, Mudali S, Iacobuzio-Donahue C, Jaffee EM, Moreno M, Pastan I, Sass PM, Nicolaides NC, Grasso L. Morphotek Inc., 210 Welsh Pool Road, Exton, PA, USA.

Mesothelin targeted cancer immunotherapy.
Hassan R, Ho M. Solid Tumor Immunotherapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892-4264, USA. hassanr@mail.nih.gov


Believe in a Cure!

Contact us here for immediate expert help and a free copy of the book "100 Questions & Answers About Mesothelioma."

(877) END-MESO
(877) 363-6376